Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Biotechnology

Healthcare
$8.44 +3.04%

+$0.26 today

Market cap
$547.12M
Beta
1.80
P/E (TTM)
-1.7
EPS (TTM)
-$5.11
52W Low $5.37High $17.58

Volume 2.36M

Average 1.24M

DNA Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Ginkgo Bioworks Holdings, Inc.NYSE: DNA

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 59.56M shares rose 9.8% year over year, ahead of the +7.5% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 7.4% from the prior quarter. Over 3 fiscal years it compounded at +9.8% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +9.8% holds above the trailing-twelve-month pace of +7.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
59.56M+7.4% QoQ
Last fiscal yearDec 2025
55.46M+6.9% YoY
LTMMar 2026
56.38M+7.5% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.8%——
1 year+6.9%——
3-year CAGR+9.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
55.46M USD
Year-over-year change
+6.9%
4-year CAGR
+13.9%

Weighted Avg Shares vs competitors

How DNA compares with its peers on the latest reported figures

  • DNA's LTM Mar 2026 weighted avg shares of 56.38M shares is the 8th highest of the 10 companies compared; the peer median is 83.89M shares.
  • Its year-over-year change of +7.5% is the 7th highest of 10, against a peer median of +18.5%.
  • Over three fiscal years its annual growth of +9.8% compares with a peer median of +6.9%.
DNA Competitors Peer median
Weighted Avg Shares for DNA and competitors
Company Period LTM YoY 3-year CAGR
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026432.9M +30.6%+30.9%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026146.04M +2.7%+3.3%
VIRVir Biotechnology, Inc.LTM Mar 2026140.99M +3.1%+1.5%
REPLReplimune Group, Inc.LTM Dec 202589.05M +21.7%+15.6%
VALNValneva SELTM Mar 202683.89M +18.5%+13.4%
MGTXMeiraGTx Holdings plcLTM Mar 202680.99M +13.7%+21.2%
ARVNArvinas, Inc.LTM Mar 202668.65M -4.9%+6.9%
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 202656.38M +7.5%+9.8%
MBXMBX Biosciences, Inc. Common StockLTM Sep 202644.83M +33.4%+4.6%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 202640.11M +19.2%+4.7%
Peer median (excluding DNA) 83.89M+18.5%+6.9%

Competitors are the stored peer set for DNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue313.84M477.71M251.46M227.04M170.16M
Cost of Revenue129.69M204.22M54.01M38.55M31.52M
Gross Profit184.15M273.49M197.45M188.49M138.63M
Gross Margin58.7%57.3%78.5%83.0%81.5%
Research & Development1.15B1.05B580.62M424.06M243.77M
Selling, General & Admin862.95M1.43B385.03M246.16M183.29M
Operating Expenses2.01B2.48B1.06B748.25M453.91M
Depreciation & Amortization29.08M61.63M71.55M63.02M58.99M
EBITDA(1.81B)(2.06B)(821.29M)(484.39M)(254.61M)
EBITDA Margin-575.7%-431.2%-326.6%-213.3%-149.6%
Operating Income(1.83B)(2.21B)(864.41M)(559.76M)(315.28M)
Operating Margin-582.6%-462.4%-343.8%-246.5%-185.3%
Interest Income837K20.26M57.22M38.61M22.62M
Interest Expense2.37M106K93K94K0
Other Income / Expenses(9.66M)87.55M(28.53M)12.25M1.68M
Income Before Tax(1.84B)(2.12B)(892.94M)(547.51M)(313.6M)
Pre-Tax Margin-585.7%-444.1%-355.1%-241.1%-184.3%
Income Tax Expense(1.48M)(15.03M)(71K)(479K)(837K)
Net Income(1.83B)(2.1B)(892.87M)(547.03M)(312.76M)
Net Margin-583.1%-440.6%-355.1%-240.9%-183.8%
EPS (Basic)(53.83)(50.15)(18.37)(10.54)(5.64)
EPS (Diluted)(55.53)(50.20)(18.40)(10.54)(5.64)
Weighted Avg Shares32.95M41.93M48.53M51.89M55.46M
Weighted Avg Shares (Diluted)34.01M42M48.61M51.89M55.46M

Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Intrinsic Alpha fair value

Locked

Current Price

$8.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.